An international team of researchers at the University of Manchester, Baylor College of Medicine and collaborating ...

An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

Tenax Therapeutics progresses levosimendan for PH-HFpEF with Phase 3 trials, aiming for a first-of-its-kind therapy. Click ...

An international team of researchers at the University of Manchester, Baylor College of Medicine and collaborating institutions has discovered a ...

Researchers have discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

Whereas obesity is a common confounder when interpreting natriuretic peptide values, and the presence of atrial fibrillation has an important influence on pretest probability, other confounders are ...

Heart failure with preserved ejection fraction (HFpEF) is a disease in which the left ventricle (LV) of the heart shows impaired relaxation during cardiac diastole, often accompanied by structural and ...

Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes or ...

In patients with heart failure with improved ejection fraction (EF), pharmacological therapy is rarely withdrawn, according to a study published online March 17 ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

Title : Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients. Session : Late-breaking science in heart failure, cardiomyopathies, pulmonary ...